IP Library Granted Patent US 10,130,635
Granted Patent B2
US 10,130,635 · App. 15/073,324 · Granted Nov 20, 2018

Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals

Inventors: Jayaraman V. Raman (Vadodara, IN); Swaroop K. Vakkalanka (La Chaux-de-Fonds, CH)
Assignee: RHIZEN PHARMACEUTICALS SA
A61K31/5377A61K31/352A61K31/52C07B55/00C07D311/58C07D473/34C07D487/14C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,635
App. No.
15/073,324
Granted
Nov 20, 2018
Kind
B2
Abstract

The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

Claims (39)

1. A compound of formula (IA) or (IB)

or a salt thereof, wherein

each occurrence of R is independently selected from hydrogen, halogen, and unsubstituted alkyl;

R 1 is unsubstituted C 1-6 alkyl;

Cy 1 is substituted or unsubstituted phenyl; and

n is an integer selected from 0, 1, 2, 3 or 4,

wherein the compound is not selected from

or a salt thereof.

2. The compound of claim 1 , wherein R is unsubstituted alkyl or halogen and n is 1.

3. A compound of claim 1 , wherein

R is fluoro or methyl;

Cy 1 is

and

R 1 is methyl or ethyl.

4. A compound of claim 1 , wherein R 1 is methyl or ethyl.

5. A compound of claim 1 , wherein n is 1.

6. A compound of claim 1 , wherein the compound has an enantiomeric excess of at least 75%.

7. A compound selected from

(R)-6-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one;

(R)-2-(1-hydroxyethyl)-5-methyl-3-phenyl-4H-chromen-4-one;

(R)-6-fluoro-2-(1-hydroxyethyl)-3-phenyl-4H-chromen-4-one;

(R)-2-(1-hydroxyethyl)-3-phenyl-4H-chromen-4-one;

(R)-3-(3-fluorophenyl)-2-(1-hydroxypropyl)-4H-chromen-4-one;

(R)-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one;

(S)-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one;

and salts thereof.

8. A compound of claim 1 , wherein the compound has an enantiomeric excess of at least 90%.

9. A compound of claim 1 , wherein the compound has an enantiomeric excess of at least 95%.

10. A compound of claim 1 , wherein the compound has an enantiomeric excess of at least 97%.

11. A compound of claim 1 , wherein the compound has an enantiomeric excess of at least 98%.

12. A compound of claim 1 , wherein Cy 1 is unsubstituted phenyl.

13. A compound of claim 1 , wherein Cy 1 is 3-fluorophenyl.

14. A compound of claim 1 , wherein

R is fluoro or methyl;

n is 0 or 1;

Cy 1 is

and

R 1 is methyl or ethyl.

15. A compound of claim 1 , wherein Cy 1 is unsubstituted phenyl or fluoro-substituted phenyl.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 6, 2021
From: RHIZEN PHARMACEUTICALS AG
To: RHIZEN PHARMACEUTICALS AG
Reel/Frame 057836/0286 →
CHANGE OF ADDRESS Recorded Mar 22, 2021
From: RHIZEN PHARMACEUTICALS SA
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 056775/0375 →
Priority Claims (1)
IN 1737/CHE/2012 · May 4, 2012 · national
Continuity (4)
Continuation 14398902
Provisional Application 61671956 · Jul 16, 2012
Related Publication 20170266196A1 · Sep 21, 2017
Related Publication 20180098994A9 · Apr 12, 2018